Government considers hiking price of alcohol and banning adverts
A draft version of the document, seen by Sky News, implied a total or partial ban on adverts for alcohol has been considered. It is not yet known whether the initiative will be included in the final version of the plan.
Campaigners welcomed the prospect of a ban, saying UK regulations on alcohol advertising are 'far weaker' compared to other countries. Sky also reported minimum alcohol pricing was considered by officials but it is understood this will not be included in the plan.
READ MORE: Abandoned UK airport to reopen offering cheap Ryanair and easyJet flights to Europe
READ MORE: Prison officer who guarded Lucy Letby on her first night in jail says she was nothing like she seems
Commenting on the reports, Dr Richard Piper, chief executive of Alcohol Change UK, said: 'We must face facts: alcohol is a leading health polluter in the UK, affecting the quality of life and health of millions, while cutting too many lives short.
'Despite total consumption going down, alcohol harm is still going up. The status quo, including our far weaker advertising regulations compared to other countries, isn't working. Alcohol is everywhere: from sponsorship of prime-time TV shows and sporting events, highly visible advertising as we travel to and from work or school, and incessant online marketing that is almost impossible to turn off.
'All the while, endless associations between alcohol and relaxing, socialising, celebrating or commiserating have the effect of glamorising and normalising alcohol, falsely suggesting it is 'essential' to our lives.
'Too many children and young people are exposed to alcohol advertising, especially through sports sponsorship and online. This is totally unacceptable, and the public strongly supports action to protect our children from these tactics so they can enjoy an alcohol-free childhood as they grow and develop. 'Our kids should no longer be the collateral damage of alcohol marketing.
'Combined with wider measures to unlock better public health, reduce crime and strengthen our economy, we hope to see Government's 10-Year Health Plan and Health Mission Board on Alcohol address out of control industry advertising.
'This is a real opportunity to move alcohol out of the spotlight and reduce harm for millions of people.'
A spokesperson for Portman Group, which represents the alcohol industry, said in a statement: 'The vast majority of people drink within the chief medical officer's weekly guidelines. As such, we're not in favour of broad, sweeping measures that impact that moderate majority whilst ignoring the needs of those who drink at the most harmful levels.
'We are deeply concerned by the figures that tell us that 3% of the UK population drink 30% of total alcohol consumed and so we support the use of targeted measures to manage the complex, often interrelated issues resulting in harmful consumption.
'The industry already takes responsible marketing very seriously and we look forward to engaging if there are future consultations around this to ensure we can continue to protect consumers.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
LAUSANNE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of 2025 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at The archived webcast will be available for 30 days following the call. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA and a PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker. Headquartered in Lausanne (Biopôle), Switzerland, with operations in London and New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at and follow us on LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the expected cash runway into 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for our exatecan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS:Investors and MediaNicole RileyADC 862-926-9040 View original content to download multimedia: SOURCE ADC Therapeutics SA Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
RSV symptoms as 'serious virus' coming to UK after Australia surge
NHS experts have urged people who are eligible for a vaccine against respiratory syncytial virus (RSV) to take it up after cases surged in Australia. Australia saw a record number of RSV cases last year, and NHS officials have suggested that the Australian winter often provides a good indication of how viruses will spread in England. Since the start of 2025, the virus has been progressively spreading, with nearly half of reported cases occurring in children under five years old. Kate Brintworth, chief midwifery officer for NHS England, said: "Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating." READ MORE: Walker spots giant 'alien' jellyfish washed up on beach READ MORE: Warning over serious virus affecting newborns after surge in cases Dr Andy Whittamore, GP and clinical lead at Asthma + Lung UK, who has pointed out the key symptoms to watch out for and shared some strategies to help protect yourself and your family. What is RSV? He said: "Respiratory syncytial virus is a virus that causes symptoms very similar to the common cold, most of us get it at some point and don't even know that we've had it." According to Asthma + Lung UK, up to 9 in 10 children will contract RSV before they turn two years old and around 175,000 people over the age of 65 visit their GP about RSV each year. How does it spread? Dr Whittamore said: "Like most respiratory viruses, RSV spreads by people coughing and sneezing droplets from their own respiratory tract and it is spread to other people that way, It is often spread and caught in the air, by contact or if it ends up on surfaces." While RSV can circulate all year round, it typically peaks during the colder months. He said: "We see a major peak in cases in the NHS between October and February, particularly in December/January time." What are the most common symptoms? "As a GP, I see a lot of people with respiratory viruses and you can't really tell whether it's flu, Covid, RSV or the common cold," Dr Whittamore says. "Common symptoms are a runny nose, blocked nose, sneezing, coughing, feeling tired etc. People might also have a fever with it and if it's affecting their respiratory system itself, they might experience breathless or wheezing as well." A high temperature is also another key sign to look out for, according to the NHS website. Dr Whittamore said: "For most people, these symptoms tend to last no more than a week to 10 days." Can it lead to any serious complications? RSV can lead to some serious complications such as pneumonia or bronchiolitis for high-risk groups such as babies, young children and older people. Dr Whittamore said: "What we see with RSV, especially in younger children under the age of two, is that it can cause bronchiolitis, which causes quite dramatic breathing effects which can quite often put people in hospital. "We are also seeing that RSV is having a big impact on people over 75. We know that in that age group, the virus is more likely to cause them problems with their breathing and could go on and cause pneumonia and is likely to increase their chances of going to hospital." The NHS website also states that individuals with weakened immune systems, or long-term lung or heart conditions, and those who smoke tobacco are also at risk. A more serious infection (such as pneumonia or bronchiolitis) may cause a cough that gets worse, shortness of breath, noisy breathing (wheezing), faster breathing or long gaps between breaths, difficulty feeding in babies or loss of appetite, and confusion in older adults, according to the NHS website. How is it treated? RSV often improves on its own in one or two weeks, so you can usually manage it at home. Dr Whittamore said: "One important thing to do is to keep well hydrated, people with RSV should be pushing their fluids, resting more, taking paracetamol and can usually monitor themselves. However, if you are worried about yourself or your child, then seek advice from your GP or call 111." Can it be prevented? There are some measures you can take to reduce your chances of contracting RSV or spreading it to anyone else. Dr Whittamore said: "Make sure that when you are blowing your nose or sneezing that you use a tissue and throw it away, also, remember to wash your hands and clean surfaces regularly." The GP emphasises that the most crucial way to prevent people from falling ill with RSV is to ensure you receive the RSV vaccination if you are eligible for it. The RSV jab is recommended if you're expecting (from 28 weeks of pregnancy) – to help safeguard your baby for the first few months after they're born – or if you're aged between 75 and 79. Fresh research from the UK Health Security Agency (UKHSA) has revealed the RSV vaccine is around 82% effective in preventing older people being hospitalised with an RSV infection. "Most GP practices are contacting people and inviting them in, but if somebody thinks they're eligible and haven't been contacted they should contact their GP surgery and see if they can get it booked in," recommends Dr Whittamore.
Yahoo
an hour ago
- Yahoo
Kate's ‘Severe' Cancer Side Effect Sparks New Health Concerns: ‘Clearly She's Not Well'
New reports about the British royal family have all focused on the relationships. Prince Harry and King Charles are reportedly closer to reconciliation. Prince William, however, doesn't seem all that ready to make nice with his brother. Amid all of those conversations, the health issues have fallen to the back burner. But that doesn't mean King Charles and Kate Middleton's cancer battles can be forgotten. And now, Kate's health is drawing renewed attention months after her reported cancer remission. reported there is growing concern that the Princess of Wales is not OK. 'Kate is painfully thin, and people are worried it's a sign that she is struggling with her recovery from cancer treatment – or worse, she's had a relapse,' an insider told the outlet. More from StyleCaster Kate Middleton's Parents' Futures Revealed Amid Speculation Over What Their Titles Will Be Once She Becomes Queen William & Kate Reportedly Looking into Moving After Rumors Harry & Meghan Are Relocating Back to the UK Related: Did William really cheat on Kate? Sources claimed Kate now weighs around 90 pounds. 'She's been through so much, and she wants to be there for the royal family and do her part, but clearly she's not well,' the source added. 'Word is she's having a difficult time and has no appetite and is losing weight as a result. She's gaunt and has little to no muscle tone. Kate always had an athletic figure, but she's far from it now.' Dr. Gabe Mirkin, who has not treated the princess, told the outlet this could be a sign she isn't responding well to treatment. 'Kate is severely underweight at around 90 pounds, 19 months after abdominal surgery, cancer, and chemotherapy. This severe weight loss can be caused by the chemotherapy itself, not eating enough because she doesn't feel very well, or treatment failure for her cancer,' Mirkin explained. 'The severe loss of fat, muscle, and bone can interfere with her own immunity's ability to cure the cancer.' Since entering remission, Kate has made a gradual return to public life, being present at certain events while skipping others, like the Royal Ascot. And yet, it was her appearance at Wimbledon that first caused concern. 'It seems to be a case of too much too soon,' the insider told the outlet. 'Clearly, Kate needs rest, and she needs nourishment.' The Princess recently discussed her cancer recovery with patients and staff members of the NHS in June 2025. 'You put on a sort of brave face, stoicism through treatment,' she explained. 'Treatment's done, then it's like, 'I can crack on, get back to normal,' but actually, the phase afterwards is really, really difficult.' 'You're not necessarily under the clinical team any longer, but you're not able to function normally at home as you perhaps once used to,' she explained, in words that seem really important now. 'And actually, someone to help talk you through that, show you, and guide you through that sort of phase that comes after treatment, I think is really valuable.' 'You have to find your new normal and that takes time…and it's a roller coaster, it's not smooth, like you expect it to be,' Kate added. 'But the reality is you go through hard times.' Whether those hard times mean Kate would be better served by taking a step back, or might mark a return of her illness, we will have to wait and see. Hopefully, it's nothing serious and she's getting the help she needs. Best of StyleCaster The 26 Best Romantic Comedies to Watch if You Want to Know What Love Feels Like These 'Bachelor' Secrets & Rules Prove What Happens Behind the Scenes Is So Much Juicier BTS's 7 Members Were Discovered in the Most Unconventional Ways Solve the daily Crossword
